Articles From: Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005 to Ellie Mae Named to Software 500 by Software Magazine


Eleven Biotherapeutics, Inc. (Nasdaq: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the issuance of U.S. Patent No.
Sign-up for Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005 investment picks
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2014 and recent business highlights.
Sign-up for Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results investment picks
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that Abbie Celniker, Ph.D., President and Chief Executive Officer, will present a company overview at the Oppenheimer 25 th Annual Healthcare Conference in New York on Thursday, December 11, 2014 at 10:55 a.m. ET.
Sign-up for Eleven Biotherapeutics to Present at Oppenheimer 25th Annual Healthcare Conference investment picks
Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced it will report third quarter 2014 financial results on Thursday, November 13, 2014.
Sign-up for Eleven Biotherapeutics to Report Third Quarter 2014 Financial Results on November 13, 2014 investment picks
Eli Lilly (LLY) said it would pay U.K. drug maker AstraZeneca (AZN) up to $500 million in development and regulatory milestone payments, as part of a new agreement to co-develop and commercialize AstraZeneca's Alzheimer's treatment.
Sign-up for Eli Lilly agrees to co-develop AstraZeneca's Alzheimer's treatment investment picks
Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enroll more than 1,500 patients in 15 countries INDIANAPOLIS , Dec.
Sign-up for Eli Lilly and Company and AstraZeneca Initiate Pivotal Clinical Trial for Patients with Early Alzheimer's Disease investment picks
Drug maker Eli Lilly & Co.
Sign-up for Eli Lilly profit sinks 58%, revenue declines investment picks
Eli Lilly (LLY) and AstraZeneca (AZN) announced the initiation of a late-stage trial for its treatment for Alzheimer's disease.
Sign-up for Eli Lilly, AstraZeneca launch patient trial for Alzheimer's treatment investment picks
By Michael Calia Eli Lilly and Co.
Sign-up for Eli Lilly, Incyte arthritis drug meets endpoint in late-stage trial investment picks
Morgan Stanley analyst David Risinger made a bullish U-turn on Eli Lilly's stock (LLY) on Thursday, upgrading it to overweight after being at underweight for three years, because of increased optimism about the pharmaceutical giant's drug pipeline.
Sign-up for Eli Lilly's stock rating goes from bearish to bullish at Morgan Stanley investment picks
2014/10/30
Some of the largest registered investment advisors (“RIAs”) not only expect industry consolidation to accelerate in the coming year, many plan to contribute to this trend directly by making an acquisition, according to a survey conducted by TD Ameritrade Institutional 1 during its 2014 Elite Summit.
Sign-up for Elite Advisors Say Scalability, Succession Needs Will Fuel More RIA Deal Activity investment picks
GREENVILLE, S.C., Dec.
Sign-up for Elite Imaging Selects Comprehensive eRAD Platform investment picks
NORTHVALE, N.J., Oct.
Sign-up for Elite Pharmaceuticals Announces New Management Appointments investment picks
Revenues increase by 8% NORTHVALE, N.J., Nov.
Sign-up for Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2015 investment picks
Wells Fargo & Company (NYSE:WFC) today said that its board of directors has elected Elizabeth A.
Sign-up for Elizabeth A. Duke Elected to the Board of Wells Fargo & Company investment picks
Elizabeth Arden, Inc. (NASDAQ:RDEN), a global prestige beauty products company, today announced financial results for its first fiscal quarter ended September 30, 2014.
Sign-up for Elizabeth Arden, Inc. Announces First Quarter Fiscal 2015 Results investment picks
NEW YORK , Dec.
Sign-up for Elizabeth Arden, Inc. Signs Supermodel Karlina Caune As Brand Ambassador investment picks
2014/10/15
WEST CHESTER, Pa.
Sign-up for Ellen DeGeneres Launches Seasonal Home Collection With QVC investment picks
Campbell Soup Company (NYSE:CPB) today announced that Ellen Oran Kaden, Senior Vice President – Chief Legal and Public Affairs Officer, has informed the company of her decision to retire from Campbell on May 1, 2015.
Sign-up for Ellen Oran Kaden to Retire from Campbell on May 1, 2015 investment picks
Ellie Mae® (NYSE:ELLI), a leading provider of innovative on-demand software solutions and services for the residential mortgage industry, announced that it has recently surpassed 100,000 active users of its Encompass® mortgage management solution , the mortgage industry’s solution for achieving compliance, loan quality and efficiency.
Sign-up for Ellie Mae Achieves Major Milestone with 100,000 Active Encompass Users investment picks
Ellie Mae® (NYSE:ELLI), a leading provider of innovative on-demand software solutions and services for the residential mortgage industry, announced today that it has completed its acquisition of AllRegs, a leading information provider for the mortgage industry.
Sign-up for Ellie Mae Completes AllRegs Acquisition investment picks
Ellie Mae® (NYSE:ELLI), a leading provider of innovative on-demand software solutions and services for the residential mortgage industry, today announced that it has been named to the Deloitte Technology Fast 500™ list, which recognizes the fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America.
Sign-up for Ellie Mae Named to Deloitte Technology Fast 500 investment picks
Ellie Mae ® (NYSE: ELLI), a leading provider of innovative on-demand software solutions and services for the residential mortgage industry, announced it has made HousingWire’s HW Fast50™ list of the 50 fastest-growing companies in the housing industry.
Sign-up for Ellie Mae Named to HousingWire HW Fast50™ investment picks
Ellie Mae® (NYSE:ELLI), a leading provider of innovative on-demand software solutions and services for the residential mortgage industry, today announced that it has been named to Software Magazine’s 2014 Software 500, a ranking of the top global software and service providers, now in its 32 nd year.
Sign-up for Ellie Mae Named to Software 500 by Software Magazine investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Eleven Biotherapeutics Granted U.S. Composition-of-Matter Patent for EBI-005 to Ellie Mae Named to Software 500 by Software Magazine
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent